[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"smoking-addiction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:smoking-addiction":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,88],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100523517","early-phase-1-addictive-threshold-of-nicotine-100523517",false,"NCT06096714","Addictive Threshold of Nicotine","Inclusion Criteria:\n\n* to contact their primary care provider when necessary.\n* Adults, aged 21 to 59 years. Individuals less than 21 will be excluded because the minimum age for purchasing tobacco products is 21 in our state. The upper age is set at 59 because there are no previous IV nicotine studies that enrolled smokers over the age of 59.\n* Smoking at least for one year and more frequently than once a week, smoking status confirmed with a semi-quantitative urine nicotine test. Smokers will be stratified based on the level of dependence, assessed with the FTND scores (Heatherton et al. 1991) (low or no dependence 4 and moderate or high level of dependence 5.\n* In good health as verified by medical history, screening examination, and screening laboratory tests.\n* For women, report using acceptable birth control methods.\n\nExclusion Criteria:\n\n* History of major medical or psychiatric disorders that the physician investigator deems as contraindicated for the participant to be in the study\n* regular current use of certain psychotropic medications (such as mood stabilizers, antipsychotics, or anxiolytics being prescribed to treat bipolar disorder, psychosis or anxiety spectrum disorders, respectively)\n* current untreated alcohol or substance use disorder for any other recreational or prescription drugs other than nicotine\n* for women, pregnant as determined by pregnancy screening, or breastfeeding\n* seeking (or undergoing) treatment for tobacco dependence or smoking.","ALL","21 Years","59 Years",{"count":19,"type":20},45,"ESTIMATED","INTERVENTIONAL",[23],"EARLY_PHASE1","To determine the nicotine threshold dose(s) for discrimination, subjective-rewarding effects, -and reinforcement in smokers with different levels of dependence.",[26],"Smoking Addiction","RECRUITING","2026-06-09",{"date":30,"type":31},"2026-06-11","ACTUAL",{"date":33,"type":31},"2024-02-27",{"date":35,"type":20},"2027-10-01",{"name":37,"class":38},"Yale University","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":63,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":4},"100638763","smoking-cessation-with-wearables-to-improve-general-oral-health-and-quality-of-life-100638763","NCT07593742","Smoking Cessation With Wearables to Improve General, Oral Health and Quality of Life","Smoking Cessation Programme in Telerehabilitation Assisted by Telemonitoring With Non-Invasive Wearable Devices for the Improvement of Oral Health, General Health and Quality of Life","Wear-Smile","Inclusion Criteria:\n\n* Subjects who smoke ≥ 5 cigarettes per day (traditional or equivalent in nicotine content in non-combustible tobacco or liquid\u002Fvape), regardless of the severity of nicotine dependence\n* Subjects ≥ 18 years of age\n* Ability and willingness to provide informed consent or presence of a legal representative who consents\n* Subjects in possession of home medical devices for measuring cardiopulmonary parameters (sphygmomanometer and pulse oximeter) (requirement applicable to participants assigned to the control group)\n\nExclusion Criteria:\n\n* Age \\\u003C 18\n* Pregnant or breastfeeding women\n* Subjects with a remote or current history of using smoking cessation methods\n* Subjects with acute dependence on alcohol or other substances of abuse other than nicotine\n* Pathologies with advanced neurocognitive degeneration\n* Unstable psychiatric conditions (subjects with active suicidal ideation, hospitalization for psychiatric reasons and\u002For changes in psychiatric medication for less than 3 months)\n* Inability or refusal to sign informed consent\n* Inability to access the integrated telemedicine platform and\u002For wearable remote monitoring devices (requirement applicable to participants assigned to the experimental group)","18 Years",{"count":50,"type":20},102,[52],"NA","Tobacco smoking remains one of the leading preventable causes of disease, disability, and premature death worldwide. According to the World Health Organization, tobacco use is responsible for more than eight million deaths each year globally, including deaths caused by direct smoking and exposure to secondhand smoke. Smoking is a major risk factor for a wide range of chronic diseases, including cardiovascular diseases, chronic respiratory diseases, several types of cancer, and numerous oral health conditions. In addition to systemic effects, tobacco use is strongly associated with oral potentially malignant disorders and oral squamous cell carcinoma, representing a significant burden for public health systems.\n\nDespite the well-documented health risks, smoking cessation remains difficult for many individuals due to the addictive properties of nicotine and the complex behavioral and psychological components associated with tobacco dependence. Multimodal smoking cessation programs that combine behavioral counseling, psychological support, and continuous monitoring have been shown to increase the likelihood of successful cessation. However, access to these programs may be limited by logistical barriers, including geographic distance, time constraints, and limited availability of specialized services.\n\nIn recent years, telemedicine and digital health technologies have emerged as promising tools to support healthcare delivery and improve access to treatment programs. Telemedicine platforms allow remote interaction between patients and healthcare professionals, facilitating communication, follow-up, and monitoring of patients over time. Additionally, wearable devices and remote monitoring systems enable the collection of physiological and behavioral data outside traditional clinical settings, providing clinicians with valuable information to support personalized interventions.\n\nThe aim of this study is to evaluate the effectiveness and feasibility of a smoking cessation program delivered through a telerehabilitation model supported by an integrated telemedicine platform and wearable remote monitoring devices. The program is designed to support individuals who smoke tobacco products, including both combustible tobacco and alternative nicotine-containing products, by providing behavioral and psychological interventions combined with continuous remote monitoring.\n\nParticipants enrolled in the study will be assigned to one of two groups. The intervention group will participate in a telerehabilitation program delivered through a dedicated telemedicine platform. This program will include structured behavioral and psychological treatment sessions aimed at supporting smoking cessation, along with remote monitoring through non-invasive wearable devices that allow healthcare professionals to track selected physiological parameters and patient engagement during the treatment process.\n\nThe control group will receive the same multimodal behavioral and psychological treatment program but delivered through conventional rehabilitation methods without the use of telemedicine technologies or wearable monitoring devices.\n\nBy comparing these two approaches, the study aims to explore whether the integration of telemedicine and wearable technologies into smoking cessation programs may improve patient engagement, facilitate monitoring, and potentially enhance the effectiveness of behavioral interventions aimed at reducing tobacco use. The findings of this study may contribute to the development of innovative digital health strategies for smoking cessation and provide evidence to support the integration of telemedicine into addiction treatment and preventive healthcare programs.",[55,56,57,58,59,26,60,61,62],"Smoking ( Cigarette)","Smoking (Tobacco) Addiction","Smoking Behaviors","Smoking Cessation","Smoking Dependence","Smoking Cessation Intervention","Smoking E-cigarette","Smoking Abstinence",[64,65,66,67,68,69,70,71,72,73,74,75,76,77],"Smoking","Smoking cessation","Smoking addiction","Tobacco","Wearable device","Telerehabilitation","Oral Health","Periodontal Health","General Health","Quality of life","Periodontal disease","E-cigarette","Heat not burn tobacco","Smoking abstinence","NOT_YET_RECRUITING","2026-05-11",{"date":81,"type":31},"2026-05-18",{"date":83,"type":20},"2026-06-01",{"date":85,"type":20},"2027-11-01",{"name":87,"class":38},"University of Salerno",{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":21,"phases":97,"briefSummary":98,"conditions":99,"keywords":100,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":113},"100576764","evaluation-of-the-effectiveness-of-routine-nurse-education-in-prescribing-nicotine-replacement-therapy-for-hospitalized-smokers-in-a-university-hospital-100576764","NCT06789536","Evaluation of the Effectiveness of Routine Nurse Education in Prescribing Nicotine Replacement Therapy for Hospitalized Smokers in a University Hospital","NICOTINURSE","Inclusion Criteria:\n\n* An active smoking patient (daily or occasional tobacco use) hospitalized in the following departments: hypertension\u002Fvascular medicine, nephrology, pulmonology, or the coronary care unit (CCU).\n* Patient residing in the Île-de-France region.\n* Proficient in the French language.\n* Has signed informed consent.\n\nExclusion Criteria:\n\n* Patient not affiliated with social security;\n* Patient under State Medical Aid (AME);\n* Patient under legal protection measures;\n* Pregnant or breastfeeding patient;\n* Patient refusing to participate in the study.",{"count":96,"type":20},442,[52],"The goal of this study is to determine whether training nurses to prescribe nicotine replacement therapy (NRT) can increase the proportion of smoking cessation at one month after hospital discharge among active smokers (daily or occasional tobacco use) hospitalized at the European Hospital Georges Pompidou in the following departments: Hypertension\u002FVascular Medicine, Nephrology, Pulmonology, and the Cardiac Intensive Care Unit.\n\nThe main questions it aims to answer are :\n\nDoes training nursing teams in the prescription and adjustment of nicotine replacement therapy increase the proportion of smoking cessation at one month after hospital discharge, defined as a total absence of tobacco consumption for at least seven days prior to the consultation, based on self-report and confirmed by an exhaled carbon monoxide (CO) level of ≤10 ppm? We will compare the usual care provided in the targeted departments with the care provided after all nurses in these departments receive training. The training will involve teaching the prescription of nicotine replacement therapy, dose adjustment, and communication with general practitioners and\u002For community nurses through a referral letter to facilitate continued care. Nurses will also have access to a dose adjustment document to provide to patients.\n\nParticipants will be followed up at discharge and at 1, 3, and 6 months post-discharge. At each visit, they will complete questionnaires on smoking behavior, quality of life, anxiety, and depression symptoms, and an exhaled CO measurement will be performed.",[26],[64,101,102,103],"Addictology","Nicotine replacement therapy","Paramedical","2025-01-17",{"date":106,"type":31},"2025-01-23",{"date":108,"type":20},"2025-03",{"date":110,"type":20},"2028-08",{"name":112,"class":38},"Assistance Publique - Hôpitaux de Paris",4]